FDA Approves Gilead's Biannual Injection for HIV Prevention in the US
The FDA has approved Gilead's groundbreaking twice-yearly injection to prevent HIV, offering a powerful new tool in the fight against the virus with over 99.9% efficacy demonstrated in clinical trials.
On June 18, 2025, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' innovative twice-yearly injection designed to prevent HIV transmission. This landmark approval marks a significant advancement in HIV prevention strategies, providing a long-lasting alternative to daily oral medications. The injectable treatment, marketed as Yeztugo and containing the drug lenacapavir, has demonstrated in clinical trials the ability to reduce the risk of HIV infection by over 99.9% in adults and adolescents, effectively functioning like a powerful vaccine.
Pre-exposure prophylaxis (PrEP) medications have been available for over ten years, mainly in pill form requiring daily intake. However, adherence challenges have limited their impact on reducing global infection rates. This new injectable offers a promising solution by minimizing the need for frequent dosing, which could enhance compliance and broadening prevention efforts.
Despite the excitement surrounding this development, concerns about accessibility remain. Although Gilead has not announced official pricing, analysts estimate the US launch price could reach up to $25,000 annually. HIV activists are calling for the price to be significantly lowered—around $25 per year—to ensure widespread access and help end the HIV pandemic.
The approval comes at a time when U.S. funding for HIV treatment and prevention programs has been cut by the current administration, both domestically and internationally, raising questions about equitable access to this promising new tool. Still, health experts believe that this innovation could transform HIV prevention, reducing new infections and saving lives.
Source: https://medicalxpress.com/news/2025-06-gilead-yearly-hiv.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Off-the-Shelf Stem Cell Therapy Restores Immunity in Systemic Sclerosis Patient
A novel off-the-shelf stem cell therapy derived from induced pluripotent stem cells shows promising results in reversing tissue damage in a systemic sclerosis patient, offering hope for safer and quicker autoimmune treatments.
Impact of Food and Housing Insecurity on Unsafe Gun Storage Practices
Research reveals a strong link between food and housing insecurity and unsafe firearm storage practices, emphasizing the need to address social determinants to improve gun safety and community health.
Newly Identified Ovulation Regulator Shows Potential for Infertility Treatments
A groundbreaking study uncovers the role of Semaphorin 3E in ovulation, offering promising targets for infertility and contraception research.
CRISPR Gene Editing in Blood Stem Cells May Induce Premature Aging: New Insights and Solutions
New research reveals that CRISPR-Cas9 gene editing in blood stem cells can induce premature aging responses, but strategies like anti-inflammatory treatments can improve safety and efficacy for blood disorder therapies.